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Background: Coronary heart disease (CHD) and stroke are the major causes of death among
people with diabetes.
Aim: To describe the prevalence and onset of CHD and stroke among patients with type 2
diabetes mellitus (T2DM) in primary care in Norway, and explore the quality of secondary
prevention.
Design & setting: A cross-sectional study of data was undertaken from electronic medical records
(EMRs) of 10 255 patients with T2DM in general practice. The study took place in five counties of
Norway (Oslo, Akershus, Rogaland, Hordaland, and Nordland). Quality of care was assessed based
on national guideline recommendations.
Method: Summary statistics with adjustments and binary logistic regression models were used.
Results: In total, 2260 patients (22.1%) had CHD and 759 (7.4%) had stroke. South Asians had
significantly more CHD than ethnic Norwegians (29.5%, 95% confidence interval [CI] = 26.1 to 33.0
versus 21.5%, CI = 20.6 to 22.3) and other ethnic groups, and experienced onset of CHD or stroke
at a mean of 7 years before Norwegians. In 47.9% of the patients, CHD was diagnosed before
T2DM. Treatment target for low-density lipoprotein (LDL) cholesterol was reached for 30.0% and
for systolic blood pressure (SBP) for 65.1% of the patients with CHD. Further, 20.9% of patients
with CHD were present smokers, and only 5.0% of patients reached all four treatment targets (no
smoking, HbA1c 7.0%, SBP <135 mmHg, LDL-cholesterol <1.8 mmol/l).
Conclusion: The diagnosis of CHD preceded the diagnosis of T2DM in half of the patients. The
prevalence of CHD was highest and onset earlier among ethnic South Asians. More intensive
treatment of lipids, blood pressure, and smoking are needed in patients with T2DM and CHD.
How this fits in
CHD and stroke are prevalent among people with T2DM, and are generally thought to be a compli-
cation of diabetes. However, this survey found that diagnosis of CHD preceded the diagnosis of
T2DM in half of the patients. An increased prevalence and earlier onset of CHD was also
found among people of South Asian ethnicity. Only 30.0% of CHD patients reached treatment target
for LDL-cholesterol, and more intensive care is needed for people with multiple elevated risk
factors.
Introduction
CHD and stroke are the major causes of death among people with diabetes.1 T2DM has been asso-
ciated with a doubling of the risk for CHD and stroke,2 although a somewhat lower risk has
recently been reported in Scandinavia.3,4 Cardiovascular disease (CVD) among patients with T2DM
places pressure on the healthcare system,5,6 but multifactorial secondary prevention reduces mor-
bidity and years of life lost.7–9
The influence of chronic hyperglycaemia on atherosclerosis is not fully understood,10 and studies
describing the relation between the onset of CVD and of T2DM are few. There has, however, been
an increasing awareness of diagnosing T2DM among patients with CHD. Recently, statins have been
shown to exert a diabetogenic effect,11,12 which also may contribute to an increasing prevalence of
T2DM among patients with CHD.
GPs follow up most patients with T2DM in Norway; therefore, the quality of care in general prac-
tice is essential for the clinical outcomes of these patients.
The aims in the present article were: firstly, to describe the prevalence of CHD and stroke among
patients with T2DM, time of onset, and distribution according to age, sex, ethnic group, and region
in a primary care setting in Norway; and secondly, to characterise the secondary preventive efforts
among T2DM patients with CHD and stroke to identify potential treatment gaps, and identify
patient and GP factors associated with successful achievement of treatment goals.
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Method
The study is part of the ROSA 4 study, which is a cross-sectional survey assessing the quality of care
for patients with diabetes in general practice in Norway. In total, 106 practices with 367 GPs in five
counties of Norway (Oslo, Akershus, Rogaland, Hordaland, and Nordland) were invited to the study.
Detailed information about the method is available elsewhere.13
In short, a software program (Noklus) was used to identify all patients aged 18 years with a dia-
betes diagnosis (using the ICPC-2 codes: T89 for diabetes type 1 and T90 for diabetes type 2)
recorded from 2012–2014, and to capture pre-defined data from EMRs. Research nurses examined
the EMRs to verify the electronically registered data and to collect other relevant data regarding dia-
betes care. A questionnaire was used to gather GPs’ self-reported characteristics such as age, sex,
and specialist status.
Variables used in the present study include the following: patient characteristics (such as age, sex,
year of diabetes diagnosis, height, and weight); smoking status; pharmacological therapy; intermedi-
ate outcomes (including HbA1c, blood pressure, total cholesterol, LDL-cholesterol, high-
density lipoprotein [HDL]-cholesterol and triglycerides); macrovascular complications (prevalence
and year for diagnosis): CHD (angina, myocardial infarction, percutaneous coronary intervention/cor-
onary artery bypass surgery), stroke (excluding transient ischaemic attacks); and atrial fibrillation
(AF). For the majority of variables, the most recently recorded value from 1 October 2013–31 Decem-
ber 2014 was used; for smoking habits, the period was 1 January 2010–31 December 2014.
Further, Statistics Norway supplied information about country of birth and educational level. The
patient’s ethnic group was based on country of birth and was categorised as: (1) Norwegian (born in
Norway); (2) South Asian (born in Pakistan, Sri Lanka, India, and Bangladesh); and (3) other. The
patient’s education was grouped into: (1) primary or no education; (2) high school and/
or vocational training; and (3) university education.
The quality of care was assessed according to key recommendations for treatment and treatment
targets in the Norwegian guideline at the time of the survey; for example, the treatment target for
HbA1c was 7.0% (53 mmol/mol), intervention threshold for blood pressure was >140/85 mmHg
with treatment targets 135/80 mmHg. In patients with CHD, the treatment target for LDL was <1.8
mmol/l. Cardioprotective treatment with acetylsalicylic acid (ASA, commonly known as aspirin) 75
mg was recommended for T2DM with CHD.14
Statistical analyses
Crude prevalence of macrovascular complications and average adjusted prevalence with 95% CI
stratified by sex, ethnic group, and county are reported.
Pharmacological treatment and intermediate outcomes (HbA1c, BP, and lipids) are reported for
patients with CHD and stroke respectively. Descriptive statistics in the form of proportions, means
(with standard deviations), or median values (with percentiles) were used to describe the patient
characteristics by the stratification variables. Independent sample t-tests and analysis of variance
(ANOVA) were used to compare mean differences of numerical variables between different patient
groups. Associations between categorical factors were established from the c2 tests.
The generalised estimating equation (GEE) binary logistic regression models with random effects
at practice level were used to identify factors that were associated with achievement of treatment
goals. Similar models were fitted to binary data on prevalence of CHD before and after the diagno-
sis of T2DM. All models were adjusted for patient-level characteristics (for example, age, sex,
ethnic group, and education) while further adjustments using GP-level characteristics (for example,
sex, and specialist status) were done in models assessing treatment goals. The analyses were per-
formed with SPSS (version 24) and StataSE (version 15). Owing to multiple testing, the significance
level was adjusted accordingly, based on the Bonferroni correction.
Results
Seventy-seven practices (72.7% of those invited) with 282 GPs (76.3% of those invited) agreed to
participate, and provided data for 10 255 patients with T2DM. The baseline characteristics and inter-
mediate outcomes of these patients stratified according to sex and presence or absence of CHD
and stroke are presented in Table 1.
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Prevalence of CHD, stroke, and AF
In total, 2260 patients (22.1%, missing data = 25) had CHD and 759 (7.4%, missing data = 9) had
stroke reported in their EMRs (Table 1). Taken together, 30.9% of the patients had CHD, stroke, or
AF, or any combination of the three. The adjusted prevalence of CHD for males was twice the preva-
lence among females (28.7% versus 14.6%), and there were significant differences between ethnic
groups (Figure 1). These differences started at a young age and increased up to 64 years (further
information available from the authors on request). The same sex difference, although to a lesser
extent, was observed for stroke and AF. The mean age of onset for CHD and stroke was 7 years ear-
lier in South Asians than in ethnic Norwegians. The prevalence of stroke was lower in Rogaland com-
pared with the other counties.
Relation between age of onset of CHD and T2DM
The diagnosis of CHD preceded the diagnosis of T2DM by 1 year for 50.2% of the Norwegian
patients and 30.8% of the South Asian patients (Figure 2). The patients with CHD before T2DM
were older, more often male, more often smokers, and had a lower educational level compared with
the patients with CHD diagnosed after their T2DM diagnosis (additional information available from
the author on request). A similar trend was observed for stroke, although the mean age of diagnosis
for stroke was 1.8 years after the diagnosis of T2DM. For South Asians, CHD and stroke were diag-
nosed on average 4.3 years and 7.8 years after T2DM diagnosis respectively.
Intermediary outcomes, treatment, and achievement of treatment
targets for secondary prevention of CHD and stroke
Only 5% of patients reached all four targets: HbA1c <7.0%, SBP <135 mmHg or unmedicated <140
mmHg, LDL <1.8 mmol/l, and no smoking (Table 2). The treatment target for HbA1c was reached
Figure 1. Adjusted prevalence of CHD, atrial fibrillation, and stroke by sex and ethnic group. Numbers for sex are adjusted for age and clustering
within practices. Numbers for ethnic group are adjusted for age, sex, and clustering (see Table 1).
CHD = coronary heart disease.
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for 58.6% of the patients with CHD, while 65.1% achieved the SBP target. Among those who did not
reach the SBP target, 14.3% were not prescribed antihypertensive medication by their GPs (Table 3).
Treatment target for LDL-cholesterol (<1.8 mmol/l) was reached for 30.0% of the CHD patients. A
total of 77.3% of patients with CHD and 67.3% of patients with stroke used lipid-lowering agents. In
total, 20.9% of the CHD patients were daily smokers. When patients aged >80 years were excluded,
only minor changes in the percentages for treatment targets were observed (data not shown).
Patients with coexisting T2DM and CHD had more intensive antihypertensive treatment than
those without CHD (Table 3). Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angio-
tensin receptor blockers, and calcium channel blockers were more widely used in these patients,
while the proportion using thiazides was approximately equal in the two groups. Of the patients
with CHD, 74.6% used ASA.
In the models adjusted for confounders, females had an odds ratio (OR) of 0.64 (0.5 to 0.82)
(reference = males) for reaching treatment targets for LDL-cholesterol. However, females had an OR
of 1.42 (1.16 to 1.74) for reaching SBP target (Table 4). Patients in the north of Norway (Nordland)
also had lower odds for reaching the LDL-cholesterol target compared with other counties. People
of South Asian and other ethnic groups had an OR of 0.42 (0.29 to 0.7) for reaching the HbA1c tar-
get compared with ethnic Norwegians. People with a university degree had higher odds for reaching
the HbA1c and no smoking targets.
Figure 2. Proportions of patients where CHD was diagnosed 1 year previously, the same year, and 1 year after the diagnosis of
type 2 diabetes (overall and in different ethnic groups)
CHD = coronary heart disease. DM = diabetes mellitus.




In this study, about one-third of the patients with T2DM had coexisting CHD, stroke, or AF, or a
combination of these, and thus were candidates for secondary prevention. South Asians had the
highest prevalence of CHD, and had the first event 7 years earlier than ethnic Norwegians. An
important and novel finding is that in 50.2% of Norwegian patients with CHD the diagnosis of CHD
preceded the diagnosis of T2DM by 1 year. Treatment target for LDL-cholesterol was reached for
30.0% and for SBP for 65.1% of the patients with CHD. Further, 20.9% of patients with CHD were
present smokers, and only 5.0% of patients reached all four treatment targets (no smoking, HbA1c
<7.0%, SBP <135 mmHg, LDL-cholesterol <1.8 mmol/l).
For the patients with CHD, it is not obvious that CHD is a complication of T2DM. As the study is
cross-sectional, possible explanations can only be speculated about. The trends for obesity and suc-
cessive T2DM by ageing may be a factor, also among patients with CVD. CHD and T2DM have in
common risk factors such as obesity, hypertension, and dyslipidaemia. However, patients where
diagnosis of CHD preceded the diagnosis of T2DM were more often male, were older, and more
often smokers or former smokers. Prevalent pre-diabetes or undiagnosed diabetes might also lead
to CHD before the diagnosis of T2DM. Another possible explanation could be a hyperglycaemic
Table 2. Proportion of patients with type 2 diabetes attaining treatment targetsa for HbA1c, SBP, lipids, and smoking, stratified by patient status















 7.0% ( 53 mmol/mol) 89 58.6c 62.7 61.4 61.8





74 65.1 65.7 66.7 65.6




68 30 - - -
LDL-cholesterol <2.5
(mmol/l)
68 67.9c 41.5 64.3c 46.2
Lifestyle




Achieving no target 8.0 10.8 8.4 8.9
Achieving one target 92.0 90.5 91.6 91.1
Achieving two targets 63.3 64.9 66.7 66.3
Achieving three
targets
27.9 29.8 33.7 31.7
Achieving four targets 5.0 6.0 7.9 7.0
Significance tests used are c2 tests for categorical variables. aTreatment targets for patients with CHD are: HbA1c <7.0%, SBP target <135 mmHg medicated or
<140 mmHg unmedicated, LDL-cholesterol <1.8 mmol/l, no smoking. For patients without CHD, the intervention threshold for LDL-cholesterol are LDL >3.5 mmol/l, with
treatment target LDL <2.5 mmol/l. bP<0.05, cP<0.001.
CHD = coronary heart disease. LDL = low-density lipoprotein. SBP = systolic blood pressure.
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effect of drugs used for secondary prevention of CHD (such as thiazides). Recently, statin treatment
has been reported to exert such effects.11,12
Prescriptions for secondary prevention in patients with T2DM is largely in line with national rec-
ommendations with regard to medications in use. Of note, the most apparent gap in the quality of
secondary prevention was that only 30.0% of patients with CHD reached the treatment target for
LDL-cholesterol, despite more frequent use of statins than in 2005.13 Still, 31.9% of
the patients with CHD did not have the LDL-cholesterol measured within the preceding 15 months.
Among those who did not achieve the LDL-cholesterol goal, 19.4% did not use lipid-lowering drugs.
Side effects of statins, or fear thereof, might have led to lower adherence to statin therapy or to the
prescription of insufficient doses.15 It is also worth noting that, despite more prescription of antihy-
pertensive drugs compared with the previous ROSA 3 survey in 2005,13 a substantial number of
patients with CHD and stroke were still undertreated for high blood pressure.
Strengths and limitations
The ROSA 4 study is the largest study of patients with T2DM in Norway. The selection of practices
from three out of four health regions of Norway indicates that the sample is fairly representative for
patients with T2DM treated by Norwegian GPs. The invited practices varied in size, and both urban
and rural practices were included. The proportion of GPs with a specialist approval was somewhat
higher than among all GPs in Norway (67.5% versus 57.1% ). The mean number of patients on GPs’
list was close to the mean for all GPs in Norway. Trained nurses manually validated the diagnosis of
T2DM and CVD captured from the EMRs. The morbidity data were based on hospital reports, which
ensured its accuracy. Socioeconomic variables were obtained from Statistics Norway, further assur-
ing the validity of the study.
Table 3. Prescriptions during the last 15 months for primary and secondary prevention in patients with type 2 diabetes, CHD, and stroke.
Treatment











Attained SBP targets 65.7 64.1 67.0a 65.1 66.7
Blood pressure medication
Thiazides 26.4 28.2 23.9 25.8 26.7
ACE inhibitors or aII-receptor blockers 47.7 48.7 46.8 61.5b 58.0b
Calcium channel blockers (dihydropyridines) 23.1 22.3 23.8 29.1b 34.1b
Beta-blockers 16.9 19.0 14.9b 65.6b 46.1b
Other BP medication 1.6 1.2 2.0a 2.9b 2.2
Mean number of BP medications (SD) 1.2 (1.3) 1.3 1.2 2.1 (1.4)d 1.9 (1.4)d
No BP medication 42.8 39.5 46.0b 15.8b 21.6b
Patients with SBP above target, and not prescribed
medication
26.9 - - 14.3 17.3
Attainment of LDL target - - - 30 -
Lipid-lowering medication
Statin 45.5 45.6 45.4 76.7b 66.8b
Ezetimibe 1.6 1.9 1.3a 4.7b 2.6
No lipid-lowering medication 53.9 53.7 54.0 22.7b 32.7b
Anti-platelet therapy 22.8 21.6 24.1a 74.6b 66.3b
Significance test performed with Poisson regression analysis comparing medication for males versus females, CHD versus non-CHD patients, and stroke versus non-stroke
patients, respectively.
aP<0.05. bP<0.001. Significance test performed with c2 test comparing males versus females, CHD versus non-CHD, stroke versus non-stroke,
respectively.cP<0.05.dP<0.001.
ACE = angiotensin-converting enzyme. BP = blood pressure. CHD = coronary heart disease. CVD = cardiovascular disease. LDL = low-density lipoprotein. SBP = systolic
blood pressure. SD = standard deviation.
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However, the study has some limitations. It is not known why 27.4% of the practices declined to
participate. The cross-sectional design limits the potential for exploring explanatory factors for dif-
ferences in prevalence and intermediary outcomes.
Comparison with existing literature
The prevalence of CHD among patients with T2DM in the present study is comparable to findings
from Sweden16 and from Cleveland, US.17 However, in a recent US multicentre register study with
575 000 patients with diabetes,18 the prevalence of CHD was substantially higher (36.3%), possibly
reflecting a more selected population as several centres represented cardiology specialists.
The distribution of CHD and stroke by age, sex, and ethnic group in the present study is in line
with other findings.19,20
The results regarding lipids are slightly better than found in secondary care in Europe, where 80%
of CHD patients with T2DM had LDL >1.8 mmol/l.21 In a recent Norwegian post-myocardial infarc-
tion study, mean LDL-cholesterol was 2.1 mmol/l and 57% did not reach the target for LDL-
cholesterol.15
More patients from the present study had SBP <140 mmHg than in the Euroaspire III study (78%
versus 28%),21 but the findings were comparable to recent results from the large US-based Diabetes
Collaborative Registry.18
Implications for research and practice
The finding that CHD often preceded T2DM by several years calls for further research into the rela-
tionship between CHD and T2DM, and supports screening for diabetes among patients with CHD,
such as measuring HbA1c at the first event of CHD or stroke, and when CHD risk is assessed.22
Table 4. Associations between patient factors (including county of residence and education) and factors related to the GP, and the probability of
achieving treatment targets for intermediate outcomes in patients with CHD and T2DM.a
Covariates
SBP 135 or <140b LDL-cholesterol 1.8 mmol/l HbA1c 7.0% No daily smoking
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Patient factors
Age (per one year) 1.03 (1.02 to 1.04)d 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01) 1.06 (1.05 to 1.08)d
Sex (male = reference) 1.42 (1.16 to 1.74)d 0.64 (0.50 to 0.82)d 1.11 (0.92 to 1.35) 0.97 (0.73 to 1.28)
Socioeconomic factors
County (Oslo = reference)
Akershus 0.98 (0.59 to 1.61) 0.79 (0.54 to 1.15) 0.98 (0.65 to 1.47) 1.14 (0.75 to 1.72)
Rogaland 1.05 (0.61 to 1.78) 0.94 (0.67 to 1.33) 1.07 (0.81 to 1.44) 1.11 (0.74 to 1.67)
Hordaland 1.02 (0.61 to 1.72) 0.97 (0.71 to 1.34) 0.94 (0.67 to 1.32) 0.89 (0.59 to 1.34)
Nordland 1.41 (0.85 to 2.35) 0.60 (0.42 to 0.85)d 0.94 (0.74 to 1.19) 1.26 (0.83 to 1.93)
Education (Primary/no education = reference)
Secondary education 1.08 (0.86 to 1.35) 1.10 (0.86 to 1.40) 1.12 (0.94 to 1.34) 1.26 (0.96 to 1.65)
University 0.95 (0.67 to 1.33) 1.14 (0.83 to 1.56) 1.34 (1.02 to 1.76)c 1.76 (1.18 to 2.61)c
Ethnic group (Norwegian = reference)
South Asian 0.94 (0.63 to 1.41) 1.21 (0.82 to 1.80) 0.45 (0.29 to 0.7)d 1.91 (1.19 to 3.06)c
Other 1.05 (.72 to 1.54) 1.16 (0.79 to 1.58) 0.60 (0.42 to 0.86)c 1.06 (0.67 to 1.68)
GP factors
Specialty (Yes = reference)
No 1.24 (0.91 to 1.69) 0.95 (0.72 to 1.26) 0.92 (0.76 to 1.13) 1.15 (0.85 to 1.55)
Sex (Males = reference)
Females 0.81 (0.59 to 1.11) 1.20 (0.91 to 1.57) 1.02 (0.85 to 1.22) 1.34 (1.05 to 1.70)c
aMultilevel binary logistic regression analyses with four dependent variables in 2260 T2DM patients with CHD, adjusted for clustering between practices. bSystolic blood
pressure targets: <140 mmHg for patients not using antihypertensives, and <135 mmHg when medication is prescribed. cP<0.05. dP<0.001.
CI = confidence intervals. CHD = coronary heart disease. LDL = low-density lipoprotein. OR = odds ratio. SBP = systolic blood pressure. T2DM = type 2 diabetes mellitus.
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Reasons for not taking statins among people with high risk for CVD events needs more qualitative
investigation, and have implications for guidelines. Stricter treatment targets for intermediate out-
comes need to be justified by a proper balance between benefits and harms, which represents a
challenge in clinical practice. The target for LDL-cholesterol is to some extent arbitrary and GPs may
feel that the target is too ambitious for some patients.
The proportion of patients reaching all targets will inevitably decline for every new target that is
introduced, and likewise when targets for intermediate outcomes are lowered, if not counteracted
by better support for self-management and compliance, including drugs with fewer side effects.
The increased prevalence of CHD and stroke, and younger age at diagnosis, among South Asians
together with the fact that glycaemic control in South Asians is inferior compared with that of
ethnic Norwegians, highlights the need for special attention towards this group.
Clinically, the groups with the highest blood pressure (SBP >150 mmHg) have a clustering of risk
factors and are in need of more effective preventive efforts. Lifestyle interventions — including strat-
egies to support smoking cessation, intensified drug treatment, and support for better compliance —
might be needed for a substantial proportion of these high-risk patients.23
The diagnosis of CHD preceded the diagnosis of T2DM in half of the patients. Immigrants from
South Asia deserve special attention as they have inferior glycaemic control and increased preva-
lence of CHD at a younger age than the majority population. There is a potential for improvements
in secondary prevention, through more prescriptions of lipid-lowering drugs, smoking cessation, and
better care for people with multiple elevated risk factors, including high blood pressure.
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